Smarter Testing Better Outcomes
A biotech startup company with federal and private funds to develop and commercialize an innovative microfluidic technology for personalized medicine and drug discovery. Patients and their families will benefit from optimal therapeutic strategies leading to better outcomes.
The patented technology of layered microfluidic array closely mimics dynamic tumor tissue microenvironment to maintain micro-tumor growth and functions ex vivo with mid-to-high throughput.
An ex vivo microfluidic platform to predict and select candidate compounds during drug discovery process.
A clinical theragnostic platform to evaluate efficacy of drugs or drug combinations using cancer patients' biopsy samples directly for personalized medicine choice.